Oric Pharmaceuticals, Inc. Price/Book Ratio
The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.
- Oric Pharmaceuticals, Inc. price/book ratio for the quarter ending 2026-06-30 was 2.95, a 9.08% increase year-over-year.
- Oric Pharmaceuticals, Inc. price/book ratio for the quarter ending 2026-03-31 was 3.15, a 74.53% increase year-over-year.
- Oric Pharmaceuticals, Inc. price/book ratio for the quarter ending 2025-12-31 was 2.1, a 11.00% decline year-over-year.
- Oric Pharmaceuticals, Inc. price/book ratio for the quarter ending 2025-09-30 was 2.87, a 8.77% increase year-over-year.
- Oric Pharmaceuticals, Inc. price/book ratio for fiscal 2026 was 2.95.
- Oric Pharmaceuticals, Inc. price/book ratio for fiscal 2025 was 2.1, a 11.00% decline from fiscal 2024.
- Oric Pharmaceuticals, Inc. price/book ratio for fiscal 2024 was 2.36, a 4.66% increase from fiscal 2023.
- Oric Pharmaceuticals, Inc. price/book ratio for fiscal 2023 was 2.25, a 88.59% increase from fiscal 2022.
- Available history
- 2020-06-30 to 2026-06-30
- Data captured
Historical Price/Book Ratio
Annual Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |